Women Report Not Enough Info Given About Bleeding, Pain, Mental Anguish Before

Taking Abortion Pill.

LINK

Mifepristone is the most popular and prolific abortion drug in the United States. A new peer-reviewed study from Charlotte Lozier Institute scholars, however, suggests that the hundreds of thousands of women who down those abortion pills each year don’t feel fully informed about the physical, mental, and emotional effects linked to chemical abortion.

The study notes informed consent is “a cornerstone of patient autonomy” and is allegedly heralded by abortion activist groups such as the National Abortion Federation. Yet many of the 362 women CLI surveyed after they took mifepristone reportedly desired more information about the risks and complications of abortion pills than they were offered when the drug was prescribed.

“Abortion symptoms and side effects for which women most frequently sought to gather information included pain, bleeding, failed or incomplete abortion, and desiring abortion pill reversal,” the researchers noted.

Similar complaints appeared on online search engines and in discussion forums, which researchers also reviewed as part of the study.

“I started to bleed off the medication and pass clots what was expected,” one post stated. “I ended up seeing the fetus witch [sic] has totally broke me. I didn’t expect to see it’s [sic] little tiny toes and hands perfectly formed. It’s completely made me feel rock bottom.”

Another section of the research noted that the “most prevalent emotions mentioned by women were regret, guilt, grief, anxiety, and depression.”

“I wish I could go back and change everything. I’m miserable and I can’t stop crying. I feel suicidal,” one woman wrote.

Another post detailed how a woman tried to throw up the abortion pills after taking them.

“I’m really confused and emotional over this situation is it too late?” she asked.

Mifepristone maker Danco Laboratories, the U.S. Food and Drug Administration (FDA), and corporate media insist that pregnancy-ending pills are safe. A 2025 analysis of insurance data, however, found that more than one in 10 women who take mifepristone suffer serious additional complications such as hemorrhage or infection. The risk of experiencing a life-threatening event linked to the abortion drug is at least 22 times higher than what the FDA and Danco claim.

Approximately 30 percent of women CLI surveyed experienced unexpected levels of bleeding. Another 30 percent claimed complications in the form of unanticipated pain. The study included examples from several respondents who wondered on internet forums if the heavy bleeding they experienced after taking mifepristone was normal. Others reported confusion on whether they had already passed their babies’ bodies and if they needed immediate medical intervention.

Despite more than 29 percent of participants’ belief that they “needed more information than was provided during the informed consent process” about symptoms of an incomplete abortion with retained tissue, which can lead to life-threatening complications such as sepsis, only half of the women, 50.3 percent, were examined via ultrasound after they completed their chemical abortion.

A strong majority, 97.5 percent, of the women claimed they gave informed consent about mifepristone ahead of taking it. When asked by researchers if they wanted more information about chemical abortion “than what was offered,” however, respondents “noted the need for more information.”

The women’s biggest desire for details, the study concluded, centered on “long-term effects, mental health care and services, counseling, coping post-abortion, expected level of pain and trauma, risk of infection, pros and cons of medical versus surgical abortion, available options (e.g., ‘if i wanted to keep the baby/help me change my mind’), and wished that ‘ultrasound was a part of a follow up after an abortion.’”

“These findings raise real questions about whether women are being given all the information they want and need to be fully informed,” CLI senior research associate and study author Tessa Cox said. “Our results underscore a serious reality: Informed consent for abortion drugs needs to be far more than just a box to check. Given the broader context of the increasing availability of abortion drugs online and through the mail, there are serious ramifications, not only as the lives of unborn babies are ended by these drugs but also as women’s safety is put at risk. The stakes are too high for informed consent to be treated as a formality.”

Researchers were careful to note that gaps in informed consent and post-abortion examination were more apparent when women received mifepristone through the mail. It was the Biden-era FDA that made mail-order abortion possible by relaxing Risk Evaluation and Mitigation Strategy (REMs) requirements for in-person doctor visits and physician-only mifepristone prescribing.

A separate Charlotte Lozier Institute study published in May found that 81 percent of online abortion businesses mail drugs to women who are further along in pregnancy than the 10-week gestation limit set in the FDA’s mifepristone prescription requirements.